Valuation: Aligos Therapeutics, Inc.

Market Cap 7.62M 6.94M 6.4M 5.82M 10.92M 706M 11.47M 77.87M 30.95M 386M 28.6M 28M 1.21B P/E 2026 *
-0.19x
P/E 2027 * -0.22x
Enterprise Value -7.1M -6.47M -5.96M -5.42M -10.17M -657M -10.68M -72.51M -28.82M -359M -26.63M -26.07M -1.13B EV / Sales 2026 *
-0.21x
EV / Sales 2027 * -47x
Free-Float
77.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-41.90%
Current month-74.58%
1 month-75.40%
3 months-81.71%
6 months-78.63%
Current year-86.91%
1 week 1.18
Extreme 1.175
2
1 month 1.18
Extreme 1.175
5.38
Current year 1.18
Extreme 1.175
10.49
1 year 1.18
Extreme 1.175
13.69
3 years 1.18
Extreme 1.175
46.8
5 years 1.18
Extreme 1.175
416.5
10 years 1.18
Extreme 1.175
937.75
Manager TitleAgeSince
Chief Executive Officer 64 2018-02-04
Director of Finance/CFO 60 2020-05-31
Chief Tech/Sci/R&D Officer 65 2018-04-30
Director TitleAgeSince
Director/Board Member 64 2018-07-31
Director/Board Member 74 2018-07-31
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Free

Chief Technology Officer

23,310 0.4354%
3/9/26 Free

Controller/Auditor

9,450 0.1765%
3/9/26 Free

Chief Executive Officer

105,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-41.90%-86.75%-92.52% 7.62M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.48%-5.28%+21.08%+153.23% 40B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.16%

Financials

2026 *2027 *
Net sales 33.67M 30.67M 28.26M 25.7M 48.22M 3.12B 50.68M 344M 137M 1.7B 126M 124M 5.34B 6.18M 5.63M 5.18M 4.72M 8.85M 572M 9.3M 63.1M 25.08M 312M 23.18M 22.69M 981M
Net income -71.57M -65.18M -60.06M -54.64M -102M -6.63B -108M -731M -291M -3.62B -269M -263M -11.36B -115M -104M -96.19M -87.5M -164M -10.61B -173M -1.17B -465M -5.8B -430M -421M -18.19B
Net Debt -14.72M -13.41M -12.36M -11.24M -21.08M -1.36B -22.16M -150M -59.77M -745M -55.24M -54.07M -2.34B -298M -272M -250M -228M -427M -27.61B -449M -3.05B -1.21B -15.08B -1.12B -1.1B -47.33B
Projected Income Statement - Annual - Aligos Therapeutics, Inc.
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
26-11-20 US$1.220 -2.40% 106,836
26-11-19 US$1.250 -3.85% 106,042
26-11-18 US$1.300 -4.41% 109,347
26-11-17 US$1.360 -18.07% 57,480
26-11-16 US$1.660 -20.95% 139,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aligos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.220USD
Average target price
36.88USD
Spread / Average Target
+2,922.54%
  1. Stock Market
  2. Stocks
  3. ALGS Stock